Synapse - Works

Results (22057)

Tumor mutational burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab (nivo) plus ipilimumab (ipi) in first-line (1L) non-small cell lung cancer (NSCLC): Identification of TMB cutoff from CheckMate 568

Meeting Abstract

Ramalingam, S. S.; Hellmann, M. D.; Awad, M. M.; Borghaei, H.; Gainor, J.; Brahmer, J.; Spigel, D. R.; Reck, M.; O'Byrne, K. J.; Paz-Ares, L.; more...
Cancer Research (2018)

Fulltext@MSK | Save

A personal neoantigen vaccine, NEO-PV-01, with anti-PD1 induces broad de novo anti-tumor immunity in patients with metastatic melanoma, NSCLC, and bladder cancer

Meeting Abstract

Ott, P. A.; Govindan, R.; Naing, A.; Friedlander, T. W.; Margolin, K.; Lin, J. J.; Bhardwaj, N.; Hellmann, M. D.; Srinivasan, L.; Greshock, J.; more...
Cancer Research (2018)

Fulltext@MSK | Save

Targeting poor-prognosis subtypes of prostate cancer by inhibition of DNA repair gene ribonucleotide reductase small subunit M2

Meeting Abstract

Mazzu, Y. Z.; Armenia, J.; Chakraborty, G.; Yoshikawa, Y.; Gerke, T. A.; Coggins, S. A. A.; Qiu, X.; Atiq, M.; Stopsack, K. H.; Lee, G. S. M.; more...
Cancer Research (2018)

Fulltext@MSK | Save

A multifactorial model of T-cell expansion and durable clinical benefit in response to a PD-L1 inhibitor

Meeting Abstract

Leiserson, M. D.; Syrgkanis, V.; Gilson, A. I.; Dudik, M.; Funt, S. A.; Snyder, A.; Mackey, L.
Cancer Research (2018)

Fulltext@MSK | Save

Phase I dose escalation study of 177Lu-HuMab-5B1 (MVT-1075) in combination with MVT-5873 as radioimmunotherapy (RIT) in subjects with relapsed / refractory pancreatic cancer or other CA19-9+malignancies

Meeting Abstract

O'Reilly, E. A.; Lohrmann, C.; O'Donoghue, J. A.; Borazanci, E.; Estrella, H.; Teng, R.; Melink, T.; Dorr, K.; Kearns, C.; Peterson, M.; more...
Cancer Research (2018)

Fulltext@MSK | Save

Intratumoral CYP27A1 expression in relation to cholesterol synthesis and vitamin D signaling and its association with lethal prostate cancer

Meeting Abstract

Khan, N. A.; Stopsack, K. H.; Allott, E. H.; Gerke, T. A.; Giovannucci, E. L.; Mucci, L. A.; Kantoff, P. W.
Cancer Research (2018)

Fulltext@MSK | Save

Inherited variants at 3q13.33 and 3p24.1 influences risk of diffuse large B-cell lymphoma

Meeting Abstract

Kleinstern, G.; Hildebrand, M.; Joseph, V.; Berndt, S. I.; Ghesquieres, H.; McKay, J.; Wang, S. S.; Nieters, A.; Cox, D.; Monnereau, A.; more...
Cancer Research (2018)

Fulltext@MSK | Save

Phase I study of AZD6738, an inhibitor of ataxia telangiectasia Rad3-related (ATR), in combination with olaparib or durvalumab in patients (pts) with advanced solid cancers

Meeting Abstract

Krebs, M. G.; Lopez, J.; El-Khoueiry, A.; Bang, Y. J.; Postel-Vinay, S.; Abida, W.; Carter, L.; Xu, W.; Im, S. A.; Pierce, A.; more...
Cancer Research (2018)

Fulltext@MSK | Save

Pharmacokinetic (PK), safety, and tolerability profile of DCC-2618 in a phase I trial supports 150mg QD selected for a pivotal phase III trial in gastrointestinal stromal tumor (GIST)

Meeting Abstract

Janku, F.; Heinrich, M.; Razak, A.; Gordon, M.; Chi, P.; Ganjoo, K.; von Mehren, M.; Somaiah, N.; Lee, J.; Kuida, K.; more...
Cancer Research (2018)

Fulltext@MSK | Save

A phase Ib study of miransertib (ARQ 092) in combination with anastrozole in patients with PIK3CA or AKT1-mutant ER+ endometrial or ovarian cancer

Meeting Abstract

Hyman, D.; Bonafede, M.; O'Cearbhaill, R.; Grisham, R.; Zamarin, D.; Tew, W.; Aghajanian, C.; Cadoo, K.; Friedman, C.; Savage, R. E.; more...
Cancer Research (2018)

Fulltext@MSK | Save